Immunome logo

ImmunomeNASDAQ: IMNM

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

02 October 2020

Next earnings report:

28 March 2025

Last dividends:

N/A

Next dividends:

N/A
$592.96 M
-63%vs. 3y high
69%vs. sector
-vs. 3y high
-vs. sector
-95%vs. 3y high
67%vs. sector
-53%vs. 3y high
93%vs. sector

Price

after hours | Wed, 20 Nov 2024 22:36:17 GMT
$9.50+$0.19(+2.04%)

Dividend

No data over the past 3 years
$2.91 M$3.16 M
$2.91 M-$47.10 M

Analysts recommendations

Institutional Ownership

IMNM Latest News

Immunome, Inc. (IMNM) Reports Q3 Loss, Misses Revenue Estimates
zacks.com13 November 2024 Sentiment: NEGATIVE

Immunome, Inc. (IMNM) came out with a quarterly loss of $0.78 per share versus the Zacks Consensus Estimate of a loss of $0.60. This compares to loss of $0.36 per share a year ago.

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
businesswire.com01 November 2024 Sentiment: POSITIVE

BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on October 31, 2024, the Compensation Committee of the Company's Board of Directors (the “Compensation Committee”) granted inducement awards consisting of non-statutory stock options to purchase 378,800 shares of common stock to 14 new employees under the Company's 2024 Inducement Plan. The.

Immunome to Present Poster Highlighting Preclinical Evaluation of IM-1021, a ROR1-Targeted Antibody Drug Conjugate, at the 36th EORTC-NCI-AACR Symposium
businesswire.com18 October 2024 Sentiment: POSITIVE

BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that it will present a poster highlighting preclinical evaluation of IM-1021, a ROR1-targeted antibody drug conjugate (ADC), at the 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona on October 24, 2024. Immunome expects to submit an IND for the IM-1021 program to the FDA in.

Immunome to Present at Morgan Stanley 22nd Annual Global Healthcare Conference
businesswire.com29 August 2024 Sentiment: POSITIVE

BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Clay Siegall, PhD, President and CEO of Immunome, will participate in a fireside chat at the Morgan Stanley 22nd Annual Global Healthcare Conference on Wednesday, September 4, 2024 at 5:35 P.M. Eastern Time. Interested parties can access the live audio webcast for this conference from the Investor Relations.

Immunome, Inc. (IMNM) Reports Q2 Loss, Misses Revenue Estimates
zacks.com12 August 2024 Sentiment: NEGATIVE

Immunome, Inc. (IMNM) came out with a quarterly loss of $0.49 per share versus the Zacks Consensus Estimate of a loss of $0.38. This compares to loss of $0.46 per share a year ago.

Immunome: AL102 And Other Established Protein Targets Could Drive Value
seekingalpha.com27 June 2024 Sentiment: POSITIVE

Top-line data from Part B of phase 3 RINGSIDE study, using AL102 for the treatment of patients with desmoid tumors, expected 2nd half of 2025. The global desmoid tumor market is projected to grow to $5.49 billion by 2032. IM-1021 is an antibody-drug conjugate being developed to target ROR1 expressing solid tumors; IND filing to begin a phase 1 study for this program, expected Q1 of 2025.

Immunome Announces Promotion of Max Rosett to Chief Financial Officer
businesswire.com17 May 2024 Sentiment: POSITIVE

BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company specializing in innovative targeted cancer treatments, has promoted Max Rosett to Chief Financial Officer, starting May 9. Mr. Rosett, who previously served as Executive Vice President of Operations and Interim CFO since January 2024, played a key role in Immunome's swift evolution.

Immunome, Inc. (IMNM) Reports Q1 Loss, Misses Revenue Estimates
Zacks Investment Research14 May 2024 Sentiment: NEGATIVE

Immunome, Inc. (IMNM) reported a quarterly loss of $0.34 per share, which beat the Zacks Consensus Estimate of a loss of $0.80. This is an improvement from the loss of $0.35 per share reported a year ago.

Analysts Estimate Immunome, Inc. (IMNM) to Report a Decline in Earnings: What to Look Out for
Zacks Investment Research26 April 2024 Sentiment: NEGATIVE

Immunome (IMNM) lacks the necessary combination of key elements for a potential earnings surprise in its upcoming report. Be ready for the important projections.

New Strong Sell Stocks for April 4th
Zacks Investment Research04 April 2024 Sentiment: NEGATIVE

IMNM, SLOIF and TMQ have been added to the Zacks Rank #5 (Strong Sell) List on April 4, 2023.

What type of business is Immunome?

Immunome, Inc., a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.

What sector is Immunome in?

Immunome is in the Healthcare sector

What industry is Immunome in?

Immunome is in the Biotechnology industry

What country is Immunome from?

Immunome is headquartered in United States

When did Immunome go public?

Immunome initial public offering (IPO) was on 02 October 2020

What is Immunome website?

https://immunome.com

Is Immunome in the S&P 500?

No, Immunome is not included in the S&P 500 index

Is Immunome in the NASDAQ 100?

No, Immunome is not included in the NASDAQ 100 index

Is Immunome in the Dow Jones?

No, Immunome is not included in the Dow Jones index

When was Immunome the previous earnings report?

No data

When does Immunome earnings report?

The next expected earnings date for Immunome is 28 March 2025